Pilot, open-label, single-arm clinical trial evaluating the efficacy of topical crisaborole for steroid refractory morphea

J Am Acad Dermatol. 2023 Aug;89(2):390-392. doi: 10.1016/j.jaad.2023.03.052. Epub 2023 Apr 11.

Authors

Amy J Petty¹, Drew A Emge¹, Sarah K Blanchard¹, Maria Angelica Selim², Kim Scoggins¹, Beiyu Liu³, Cynthia L Green³, Adela R Cardones⁴

Affiliations

¹ Department of Dermatology, Duke University, Durham, North Carolina.
² Division of Dermatopathology, Department of Pathology, Duke University, Durham, North Carolina.
³ Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
⁴ Division of Dermatology, Department of Internal Medicine, University of Kansas, Medical Center, Kansas City, Kansas. Electronic address: adela.cardones@duke.edu.

PMID: 37054813
DOI: 10.1016/j.jaad.2023.03.052

No abstract available

Publication types

Clinical Trial

MeSH terms

Boron Compounds / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Dermatitis, Atopic*
Humans
Ointments
Scleroderma, Localized* / drug therapy
Treatment Outcome

Substances

crisaborole
Boron Compounds
Bridged Bicyclo Compounds, Heterocyclic
Ointments